A Study of the Pharmacokinetics and Pharmacodynamics of MK1809 (1809-001)(COMPLETED)

A Double-Blind, Double Dummy, Randomized, Placebo-Controlled, Alternating Panel, Single Oral Rising Dose Study to Assess the Pharmacokinetics and Pharmacodynamics of MK1809 in Healthy Young Volunteers

The goal of this study is to identify at least one safe and well tolerated dose of MK1809 that has similar pharmacokinetic qualities as 100 mg losartan.

Inclusion Criteria:

Part 1:

• Nonsmoker for at least 6 months
• Body Mass Index (BMI) less than or equal to 29 kg/m2
• In overall good health

Part 2:

• Body Mass Index (BMI) greater than 18kg/m2 and less than or equal to 35kg/m2
• In overall good health (patients with hypertension and/or hyperlipidemia are accepted)

Exclusion Criteria:

Part 1:

• History of any cardiovascular disease or any clinically significant family history of cardiac arrhythmias or conduction abnormalities at an age less than 60 years
• History of any major endocrine, vascular, hematologic, gastrointestinal, hepatic, renal or genitourinary disease/disorder
• History of cancer
• Clinically significant history of a neurological disorder (includes epilepsy,stroke, transient ischemic attack, classic migraines)
• Active or history of a psychiatric disorder (includes depression, bipolar disorder, schizophrenia, anxiety)
• History of asthma, severe wheezing, COPD, or other pulmonary disease
• Individual or family history of bleeding or hemorrhagic diathesis, or bleeding difficulties
• Major surgery, donated blood or participated in another investigational drug(s) trial within 30 days
• Illicit drug use (including recreational); or history of drug or alcohol abuse (within 2 years)
• Nitrate therapy within 4 weeks
• History of significant drug allergy or history of food allergies

Part 2

• History of any clinically significant cardiac or cardiovascular disease (other than hypertension)
• History of any major endocrine, vascular, hematologic, gastrointestinal, hepatic, renal or genitourinary disease/disorder
• History of cancer
• History of a neurological disorder (includes epilepsy,stroke, transient ischemic attack, classic migraines)
• Active or history of a psychiatric disorder (includes depression, bipolar disorder, schizophrenia, anxiety)
• History of asthma, severe wheezing, COPD, or other pulmonary disease
• Individual or family history of bleeding or hemorrhagic diathesis, or bleeding difficulties
• Illicit drug use (including recreational); or history of drug or alcohol abuse (within 2 years)
• Surgery, significant blood loss, donated blood, or participated in another investigational drug(s) trial within 30 days
• Nitrate therapy within 4 weeks
• History of significant drug allergy